ACAD
41.2
+1.01
+2.51%
AEMD
8.68
-0.06
-0.69%
APRI
1.67
+0.03
+1.83%
ARNA
3.925
-0.06
-1.506%
ATEC
1.35
-0.01
-0.74%
CNAT
5.45
-0.01
-0.18%
CRXM
0.502
+0.012
+2.4694%
CYTX
0.661
-0.071
-9.6735%
DXCM
71.72
+0.45
+0.63%
GNMK
9.17
-0.2
-2.13%
HALO
17.35
-0.33
-1.87%
ILMN
206.08
-2.54
-1.22%
INNV
0.152
0.00
-0.0656%
INO
8.41
-0.17
-1.98%
ISCO
0.05
0.00
0.00%
ISIS
67.32
+0.61
+0.91%
LGND
88.11
-0.04
-0.05%
LPTN
0.285
-0.006
-2.0962%
MBVX
2.32
+0.06
+2.65%
MEIP
1.9
+0.01
+0.53%
MNOV
3.95
0.00
0.00%
MRTX
36.66
+0.48
+1.33%
MSTX
0.54
0.00
0.00%
NBIX
43.86
+1.1
+2.57%
NUVA
50.55
+0.93
+1.87%
ONCS
7.95
+0.35
+4.61%
ONVO
5.01
+0.05
+1.01%
OREX
4.9
-0.02
-0.41%
OTIC
24.52
+0.19
+0.78%
QDEL
21.67
-0.57
-2.56%
RCPT
164.89
+0.06
+0.04%
RGLS
14.12
+0.54
+3.98%
RMD
58.82
+0.17
+0.29%
SCIE
0.021
+0.004
+20.000%
SPHS
1.07
-0.04
-3.60%
SRNE
13.79
-0.01
-0.07%
TROV
10.96
-0.04
-0.36%
VICL
0.95
-0.005
-0.5131%
VOLC
17.99
0.00
0.00%
ZGNX
1.7
+0.21
+14.09%
ACAD
41.2
+1.01
+2.51%
AEMD
8.68
-0.06
-0.69%
APRI
1.67
+0.03
+1.83%
ARNA
3.925
-0.06
-1.506%
ATEC
1.35
-0.01
-0.74%
CNAT
5.45
-0.01
-0.18%
CRXM
0.502
+0.012
+2.4694%
CYTX
0.661
-0.071
-9.6735%
DXCM
71.72
+0.45
+0.63%
GNMK
9.17
-0.2
-2.13%
HALO
17.35
-0.33
-1.87%
ILMN
206.08
-2.54
-1.22%
INNV
0.152
0.00
-0.0656%
INO
8.41
-0.17
-1.98%
ISCO
0.05
0.00
0.00%
ISIS
67.32
+0.61
+0.91%
LGND
88.11
-0.04
-0.05%
LPTN
0.285
-0.006
-2.0962%
MBVX
2.32
+0.06
+2.65%
MEIP
1.9
+0.01
+0.53%
MNOV
3.95
0.00
0.00%
MRTX
36.66
+0.48
+1.33%
MSTX
0.54
0.00
0.00%
NBIX
43.86
+1.1
+2.57%
NUVA
50.55
+0.93
+1.87%
ONCS
7.95
+0.35
+4.61%
ONVO
5.01
+0.05
+1.01%
OREX
4.9
-0.02
-0.41%
OTIC
24.52
+0.19
+0.78%
QDEL
21.67
-0.57
-2.56%
RCPT
164.89
+0.06
+0.04%
RGLS
14.12
+0.54
+3.98%
RMD
58.82
+0.17
+0.29%
SCIE
0.021
+0.004
+20.000%
SPHS
1.07
-0.04
-3.60%
SRNE
13.79
-0.01
-0.07%
TROV
10.96
-0.04
-0.36%
VICL
0.95
-0.005
-0.5131%
VOLC
17.99
0.00
0.00%
ZGNX
1.7
+0.21
+14.09%
Home » SDBN Blog

Bioethics in Drug Development: BIO2014

Submitted by on June 24, 2014 – 6:52 am

Consider a case where a patient has a disease with high mortality and no effective treatment available. A new experimental drug is now being tested in a clinical trial. However, this is a randomized clinical trial, which means that it will have a treatment group and a placebo group (that does not get the actual drug).

via Bioethics in Drug Development: BIO2014.

Tags:

Leave a comment!

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:

<a href="" title="" rel=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> 

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.


× 9 = fifty four